Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02988024 · ClinicalTrials.gov registry record · Phase 1
Pilot BA Study of New LY03005 vs Pristiq
A Phase 1 study, sponsored by Luye Pharma Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02988024 is a Phase 1 study that has completed, run by Luye Pharma Group. The registered enrollment target is 20 participants.
The verdict
NCT02988024, a Phase 1 study, has completed, sponsored by Luye Pharma Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The objects of this study is to assess the relative bioavailability (BA) of 80 mg LY03005 oral tablets compared to 50 mg Pristiq® oral tablets after a single oral intake under fasting conditions in healthy subjects between 18 and 50 years of age.
Interventions
- DRUG LY03005
- DRUG Pristiq
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-12-07 |
| Est. Completion | 2016-12-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02988024
The ClinicalTrials.gov registry entry for NCT02988024 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Luye Pharma Group, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LY03005 is the first listed.
NCT02988024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02988024 about?
NCT02988024 is a clinical study titled "Pilot BA Study of New LY03005 vs Pristiq". The objects of this study is to assess the relative bioavailability (BA) of 80 mg LY03005 oral tablets compared to 50 mg Pristiq® oral tablets after a single oral intake under fasting conditions in healthy subjects between 18 and 50 years of age.
What is the current status of trial NCT02988024?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2016-12-07. Estimated completion is 2016-12-28.
What interventions are being tested in trial NCT02988024?
The interventions under investigation include: LY03005 (DRUG), Pristiq (DRUG).
Who is sponsoring clinical trial NCT02988024?
This trial is sponsored by Luye Pharma Group, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.